Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2025)
Historic Gross Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Q3 2025 value amounting to 93.0%.
- Tarsus Pharmaceuticals' Gross Margin fell 2600.0% to 93.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 93.26%, marking a year-over-year increase of 2900.0%. This contributed to the annual value of 92.99% for FY2024, which is 21200.0% up from last year.
- Tarsus Pharmaceuticals' Gross Margin amounted to 93.0% in Q3 2025, which was down 2600.0% from 93.92% recorded in Q2 2025.
- Over the past 5 years, Tarsus Pharmaceuticals' Gross Margin peaked at 107.1% during Q4 2021, and registered a low of 79.85% during Q3 2023.
- In the last 5 years, Tarsus Pharmaceuticals' Gross Margin had a median value of 93.92% in 2025 and averaged 94.38%.
- Its Gross Margin has fluctuated over the past 5 years, first tumbled by -111000bps in 2022, then soared by 134100bps in 2024.
- Over the past 5 years, Tarsus Pharmaceuticals' Gross Margin (Quarter) stood at 107.1% in 2021, then decreased by -10bps to 96.0% in 2022, then fell by -6bps to 90.7% in 2023, then rose by 2bps to 92.58% in 2024, then increased by 0bps to 93.0% in 2025.
- Its Gross Margin stands at 93.0% for Q3 2025, versus 93.92% for Q2 2025 and 93.35% for Q1 2025.